clinical trial · NCT05628363
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Prostate CancerCancer of the ProstateEthos Varian treatment systemAdaptive stereotactic body radiotherapyAndrogen deprivation therapy
brief summary
This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.
started
Jan 18, 2023
primary completion
Oct 25, 2025
completion
Jul 25, 2030
last updated
Jul 2, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol